An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Mauna Kea Technologies Announces the Appointment of Sacha Loiseau as Chief Executive Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Mauna Kea Technologies has appointed Sacha Loiseau, its Founder and current Chairman, as the new Chief Executive Officer, effective immediately. He replaces interim CEO Nicolas Bouvier and will hold both roles concurrently. The Board believes Loiseau's expertise will help the company capitalize on the commercial potential of its Cellvizio platform. Mauna Kea is focused on enhancing its partnerships in the medical field, aiming to provide significant clinical value globally. Loiseau has a rich history with the company, having led it for over 18 years and taking it public in 2011.
Positive
Appointment of Sacha Loiseau as CEO expected to strengthen leadership and strategic direction.
Loiseau's extensive experience could enhance partnerships with key collaborators like Johnson & Johnson.
The dual role may streamline decision-making processes within the organization.
Negative
Concerns about potential continuity issues due to the transition from an interim CEO.
Dependency on Loiseau's leadership raises risks if his performance does not meet expectations.
PARIS & BOSTON--(BUSINESS WIRE)--
Regulatory News:
Mauna Kea Technologies(Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY), inventor of Cellvizio®, the multi-disciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the appointment of Sacha Loiseau, Founder and current Chairman of the Board of Mauna Kea Technologies, to serve also as Chief Executive Officer, replacing interim CEO Nicolas Bouvier effective immediately. Mr. Sacha Loiseau will thus concurrently hold the positions of Chairman and Chief Executive Officer of Mauna Kea Technologies.
Speaking on behalf of the Mauna Kea Technologies Board of Directors, Christopher D. McFadden, Board Member and Chair of the Nomination and Remuneration Committee commented: “Our Board has unanimously asked Sacha to return to an executive leadership role where his technical expertise, global relationships and long-standing commitment to excellence will help ensure that Mauna Kea meets its full commercial and clinical potential.” Mr. McFadden added, “Mauna Kea’s partnership strategy seeks to ensure that Cellvizio’s unique clinical value proposition benefits patients globally. Building on announced collaborations with Johnson & Johnson, Telix Pharmaceuticals, On Target Labs and Tasly Pharma, we have high confidence that Sacha’s leadership will help ensure that the Mauna Kea organization is fully aligned toward meeting our collective obligations to partners, patients, providers, employees and shareholders.”
A graduate of École Polytechnique and a Ph.D. in Astrophysics, Sacha Loiseau co-founded Mauna Kea Technologies and served as its CEO for more than 18 years, taking the company public in July 2011 on Euronext. He has served as Mauna Kea Technologies Chairman of the Board of Directors since October 2018. In addition, Sacha holds other non-executive roles in leading medtech startups: he is Chairman of the Board of Therapixel and SeqOne Genomics, Board Member at Lifen, Gleamer and MDoloris. Sacha is also a Venture Partner with Elaia, a top tier DeepTech European Venture Capital firm.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and markets Cellvizio®, the real-time in vivo cell imaging platform. This technology provides unique in vivo cellular visualization that allows physicians to monitor disease progression over time, assess responses as they occur, classify areas of uncertainty and guide surgical interventions. The Cellvizio platform is used in many countries around the world and in several medical specialties and is transforming the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Techonologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 3 of Mauna Kea Technologies' 2020 Universal Registration Document filed with the Autorité des marchés financiers (AMF) on June 17, 2021 under number D-21-0566 and the amendment to the Universal Registration Document filed with the AMF on September 17, 2021, both of which are available on the Company's website (www.maunakeatech.fr ), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
